Furthermore, combining anti‐PD‐1 antibody with PF543 increased mouse survival and decreased tumor burden, suggesting that a combination of an S1P/SPHK1 blocker with anti‐PD‐1 therapy may improve the efficacy of immune checkpoint blockers in human ovarian cancer. Here, SPHK1 is linked to ovarian cancer.